Vitamin D treatment in myelodysplastic syndromes

L. Mellibovsky, A. Díez, E. Pérez-Vila, S. Serrano, M. Nacher, J. Aubía, A. Supervía, Robert R. Recker

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Myelodysplastic syndromes (MDS) are a group of clonal disturbances with defective cellular differentiation. Vitamin D3 (VD) analogues can act on the differentiation and maturity of different cell lines. We studied the effects of VD on a series of patients with MDS in an open-design trial. Nineteen patients, 12 men and seven women, with MDS were included. Patients were 74:8 ± 5.6 years (mean ± SD), seven had refractory anaemic with ringed sideroblasts, five had refractory anaemia, one had refractory anaemia with excess of blasts and six had chronic myelomonocytic leukaemia. All the patients were in a low to intermediate risk group. Mean follow-up period was 26°21 months, range 9-75. Responders were defined as follows: granulocyte or platelet count increase by 50%, or haemoglobin increase of 1.5 g/dl or transfusion needs decrease by 50%. The first five patients received 266μg of calcifediol three times a week and the other 14 received calcitriol (0.25- 0.75 μg/d). Response was observed in 11 patients. In the calcifediol- treated group, one case responded, three were non-responders, and one showed progression. In the calcitriol group, 10 were responders (two with major response), and four were non-responders. No correlation was observed between baseline levels of vitamin D metabolites and the presence of response. No hypercalcaemia was observed. Treatment with vitamin D3 metabolites could induce a long-standing response of the haematological disturbance in some low-intermediate risk MDS patients without inducing hypercalcaemia.

Original languageEnglish
Pages (from-to)516-520
Number of pages5
JournalBritish Journal of Haematology
Volume100
Issue number3
DOIs
StatePublished - 1998

Fingerprint

Myelodysplastic Syndromes
Vitamin D
Cholecalciferol
Calcifediol
Calcitriol
Hypercalcemia
Therapeutics
Leukemia, Myelomonocytic, Chronic
Refractory Anemia with Excess of Blasts
Refractory Anemia
Platelet Count
Granulocytes
Hemoglobins
Cell Line

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Mellibovsky, L., Díez, A., Pérez-Vila, E., Serrano, S., Nacher, M., Aubía, J., ... Recker, R. R. (1998). Vitamin D treatment in myelodysplastic syndromes. British Journal of Haematology, 100(3), 516-520. https://doi.org/10.1046/j.1365-2141.1998.00598.x

Vitamin D treatment in myelodysplastic syndromes. / Mellibovsky, L.; Díez, A.; Pérez-Vila, E.; Serrano, S.; Nacher, M.; Aubía, J.; Supervía, A.; Recker, Robert R.

In: British Journal of Haematology, Vol. 100, No. 3, 1998, p. 516-520.

Research output: Contribution to journalArticle

Mellibovsky, L, Díez, A, Pérez-Vila, E, Serrano, S, Nacher, M, Aubía, J, Supervía, A & Recker, RR 1998, 'Vitamin D treatment in myelodysplastic syndromes', British Journal of Haematology, vol. 100, no. 3, pp. 516-520. https://doi.org/10.1046/j.1365-2141.1998.00598.x
Mellibovsky L, Díez A, Pérez-Vila E, Serrano S, Nacher M, Aubía J et al. Vitamin D treatment in myelodysplastic syndromes. British Journal of Haematology. 1998;100(3):516-520. https://doi.org/10.1046/j.1365-2141.1998.00598.x
Mellibovsky, L. ; Díez, A. ; Pérez-Vila, E. ; Serrano, S. ; Nacher, M. ; Aubía, J. ; Supervía, A. ; Recker, Robert R. / Vitamin D treatment in myelodysplastic syndromes. In: British Journal of Haematology. 1998 ; Vol. 100, No. 3. pp. 516-520.
@article{b597beb0a5e14dea8d092ffe2c12e81c,
title = "Vitamin D treatment in myelodysplastic syndromes",
abstract = "Myelodysplastic syndromes (MDS) are a group of clonal disturbances with defective cellular differentiation. Vitamin D3 (VD) analogues can act on the differentiation and maturity of different cell lines. We studied the effects of VD on a series of patients with MDS in an open-design trial. Nineteen patients, 12 men and seven women, with MDS were included. Patients were 74:8 ± 5.6 years (mean ± SD), seven had refractory anaemic with ringed sideroblasts, five had refractory anaemia, one had refractory anaemia with excess of blasts and six had chronic myelomonocytic leukaemia. All the patients were in a low to intermediate risk group. Mean follow-up period was 26°21 months, range 9-75. Responders were defined as follows: granulocyte or platelet count increase by 50{\%}, or haemoglobin increase of 1.5 g/dl or transfusion needs decrease by 50{\%}. The first five patients received 266μg of calcifediol three times a week and the other 14 received calcitriol (0.25- 0.75 μg/d). Response was observed in 11 patients. In the calcifediol- treated group, one case responded, three were non-responders, and one showed progression. In the calcitriol group, 10 were responders (two with major response), and four were non-responders. No correlation was observed between baseline levels of vitamin D metabolites and the presence of response. No hypercalcaemia was observed. Treatment with vitamin D3 metabolites could induce a long-standing response of the haematological disturbance in some low-intermediate risk MDS patients without inducing hypercalcaemia.",
author = "L. Mellibovsky and A. D{\'i}ez and E. P{\'e}rez-Vila and S. Serrano and M. Nacher and J. Aub{\'i}a and A. Superv{\'i}a and Recker, {Robert R.}",
year = "1998",
doi = "10.1046/j.1365-2141.1998.00598.x",
language = "English",
volume = "100",
pages = "516--520",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Vitamin D treatment in myelodysplastic syndromes

AU - Mellibovsky, L.

AU - Díez, A.

AU - Pérez-Vila, E.

AU - Serrano, S.

AU - Nacher, M.

AU - Aubía, J.

AU - Supervía, A.

AU - Recker, Robert R.

PY - 1998

Y1 - 1998

N2 - Myelodysplastic syndromes (MDS) are a group of clonal disturbances with defective cellular differentiation. Vitamin D3 (VD) analogues can act on the differentiation and maturity of different cell lines. We studied the effects of VD on a series of patients with MDS in an open-design trial. Nineteen patients, 12 men and seven women, with MDS were included. Patients were 74:8 ± 5.6 years (mean ± SD), seven had refractory anaemic with ringed sideroblasts, five had refractory anaemia, one had refractory anaemia with excess of blasts and six had chronic myelomonocytic leukaemia. All the patients were in a low to intermediate risk group. Mean follow-up period was 26°21 months, range 9-75. Responders were defined as follows: granulocyte or platelet count increase by 50%, or haemoglobin increase of 1.5 g/dl or transfusion needs decrease by 50%. The first five patients received 266μg of calcifediol three times a week and the other 14 received calcitriol (0.25- 0.75 μg/d). Response was observed in 11 patients. In the calcifediol- treated group, one case responded, three were non-responders, and one showed progression. In the calcitriol group, 10 were responders (two with major response), and four were non-responders. No correlation was observed between baseline levels of vitamin D metabolites and the presence of response. No hypercalcaemia was observed. Treatment with vitamin D3 metabolites could induce a long-standing response of the haematological disturbance in some low-intermediate risk MDS patients without inducing hypercalcaemia.

AB - Myelodysplastic syndromes (MDS) are a group of clonal disturbances with defective cellular differentiation. Vitamin D3 (VD) analogues can act on the differentiation and maturity of different cell lines. We studied the effects of VD on a series of patients with MDS in an open-design trial. Nineteen patients, 12 men and seven women, with MDS were included. Patients were 74:8 ± 5.6 years (mean ± SD), seven had refractory anaemic with ringed sideroblasts, five had refractory anaemia, one had refractory anaemia with excess of blasts and six had chronic myelomonocytic leukaemia. All the patients were in a low to intermediate risk group. Mean follow-up period was 26°21 months, range 9-75. Responders were defined as follows: granulocyte or platelet count increase by 50%, or haemoglobin increase of 1.5 g/dl or transfusion needs decrease by 50%. The first five patients received 266μg of calcifediol three times a week and the other 14 received calcitriol (0.25- 0.75 μg/d). Response was observed in 11 patients. In the calcifediol- treated group, one case responded, three were non-responders, and one showed progression. In the calcitriol group, 10 were responders (two with major response), and four were non-responders. No correlation was observed between baseline levels of vitamin D metabolites and the presence of response. No hypercalcaemia was observed. Treatment with vitamin D3 metabolites could induce a long-standing response of the haematological disturbance in some low-intermediate risk MDS patients without inducing hypercalcaemia.

UR - http://www.scopus.com/inward/record.url?scp=0031864278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031864278&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1998.00598.x

DO - 10.1046/j.1365-2141.1998.00598.x

M3 - Article

VL - 100

SP - 516

EP - 520

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -